Xencor, Inc. (XNCR) Picks 400 mcg/kg RP3D for XmAb819; 45.5% cORR in ccRCC Cohort
Xencor, Inc. (XNCR) selected 400 mcg/kg IV as the proposed Phase 3 dose for XmAb819 after Phase 1 data showed 45.5% confirmed ORR and 82% 6-month PFS in ccRCC. A randomized trial vs tivozanib is planned, with potential registration-enabling study by end of 2027.
How this was made
The 30-second read
Why it matters
The dose selection and high response rates provide a tangible catalyst for the company's pipeline and may attract partnership interest.
Market read
First disclosure of Phase 3 dosing and strong early efficacy data; likely short‑term price move for XNCR.
What to watch
Regulatory timeline and potential competition from other ccRCC therapies could temper upside.
Background
Xencor is developing XmAb819, a solid‑tumor T‑cell engager targeting clear cell renal cell carcinoma.
Ticker impact
Xencor announced a Phase 3 dose of 400 mcg/kg for XmAb819 after Phase 1 data showed 45.5% ORR and 82% 6‑month PFS in a ccRCC cohort.
likely upward pressure as investors price in the promising efficacy signal.
First disclosure of a concrete Phase 3 dose and strong response rates for a biotech micro‑cap typically triggers a short‑term rally.
Market effects
reinforces confidence in T‑cell engager platforms and may lift peer biotech valuations.
U.S. biotech sector sees modest uplift.
limited to biotech investors; no broad market effect.
Counterpoint
The data set is small (n=11) and early; investors may wait for larger Phase 2/3 results before committing.
Key entities
- companyXencor, Inc.
Biotech firm developing T‑cell engager therapeutics.
- drugXmAb819
Investigational T‑cell engager for ccRCC.